The case for immunomodulatory approaches in treating HSV encephalitis

Future Virology

Volumn 8, Issue 3, 2013, Pages 259-272

  Ramakrishna, Chandran ^a   Openshaw, Harry ^a   Cantin, Edouard M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

acyclovir; encephalitis; herpesvirus; immune pathology; immunomodulation; inflammation; innate immunity; intravenous immunoglobulin; reactive oxygen species

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN; MYELOID DIFFERENTIATION FACTOR 88; PLACEBO; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; VALACICLOVIR;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MEGADOSE; ELECTROENCEPHALOGRAPHY; FUNCTIONAL NEUROIMAGING; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INCIDENCE; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84874709673     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.138     Document Type: Review

References (121)

1. Cabrera CV, Wohlenberg C, Openshaw H, Rey-Mendez M, Puga A, Notkins AL. Herpes simplex virus DNA sequences in the CNS of latently infected mice. Nature 288(5788), 288-290 (1980).
2. Deatly AM, Spivack JG, Lavi E, O'Boyle DRD, Fraser NW. Latent herpes simplex virus type 1 transcripts in peripheral and central nervous system tissues of mice map to similar regions of the viral genome. J. Virol. 62(3), 749-756 (1988).
3. Chen S-H, Yao H-W, Huang W-Y et al. Efficient reactivation of latent herpes simplex virus from mouse central nervous system tissues. J. Virol. 80(24), 12387-12392 (2006).
4. Yao H-W, Ling P, Chen S-H, Tung Y-Y, Chen S-H. Factors affecting herpes simplex virus reactivation from the explanted mouse brain. Virology 433(1), 116-123 (2012).
5. Whitley R. Herpes virus infections of the central nervous system. Herpes 11(Suppl. 2), 1-84 (2003).
6. Whitley R, Arvin A, Prober C et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases collaborative antiviral study group. N. Engl. J. Med. 324(7), 450-454 (1991).
7. Openshaw H. Neurological complications of hematopoietic cell transplantation. In: Thomas' Hematopoietic Cell Transplantation. Blume KG, Forman SJ, Appelbaum FR (Eds). Wiley-Blackwell, NJ, USA, 1653-1663 (2004).
8. Hjalmarsson A, Blomqvist P, Skoldenberg B. Herpes simplex encephalitis in Sweden, 1990-2001. Incidence, morbidity, and mortality. Clin. Infect. Dis. 45(7), 875-880 (2007).
9. Davis LE, Johnson RT. An explanation for the localization of herpes simplex encephalitis? Ann. Neurol. 5(1), 2-5 (1979).
10. Damasio AR, Van Hoesen GW. The limbic system and the localisation of herpes simplex encephalitis. J. Neurol. Neurosurg. Psychiatry 48(4), 297-301 (1985).
11. Wainwright MS, Martin PL, Morse RP et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann. Neurol. 50(5), 612-619 (2001).
12. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 13(5), 261-271 (2007).
13. Livorsi D, Anderson E, Qureshi S, Howard M, Wang Y, Franco-Paredes C. Brainstem encephalitis: an unusual presentation of herpes simplex virus infection. J. Neurol. 257(9), 1432-1437 (2010).
14. Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases collaborative antiviral study group. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. J. Infect. Dis. 171(4), 857-863 (1995).
15. Whitley R. Diagnosis and treatment of herpes simplex encephalitis. Annu. Rev. Med. 32, 335-340 (1981).
16. Skoldenberg B, Forsgren M, Alestig K et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 2(8405), 707-711 (1984).
17. Mcgrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J. Neurol. Neurosurg. Psychiatry 63(3), 321-326 (1997).
18. Raschilas F, Wolff M, Delatour FDR et al. Outcome of and prognostic factors for Herpes simplex encephalitis in adult patients. Results of a multicenter study. Clin. Infect. Dis. 35(3), 254-260 (2002).
19. Hjalmarsson A, Granath F, Forsgren M, Brytting M, Blomqvist P, Skoldenberg B. Prognostic value of intrathecal antibody production and DNA viral load in cerebrospinal fluid of patients with herpes simplex encephalitis. J. Neurol. 256(8), 1243-1251 (2009).
20. Kamei S, Taira N, Ishihara M et al. Prognostic value of cerebrospinal fluid cytokine changes in herpes simplex virus encephalitis. Cytokine 46(2), 187-193 (2009).
21. Aurelius E, Forsgren M, Skoldenberg B, Strannegard O. Persistent intrathecal immune activation in patients with herpes simplex encephalitis. J. Infect. Dis. 168(5), 1248-1252 (1993).
22. Sköldenberg B, Aurelius E, Hjalmarsson A et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J. Neurol. 253(2), 163-170 (2006).
23. Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes simplex encephalitis: pathological confirmation of viral reactivation. J. Neurol. Neurosurg. Psychiatry 74(2), 262-264 (2003).
24. Kamei S, Sekizawa T, Shiota H et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J. Neurol. Neurosurg. Psychiatry 76(11), 1544-1549 (2005).
25. Meyding-Lamade UK, Oberlinner C, Rau PR et al. Experimental herpes simplex virus encephalitis. a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J. Neurovirol. 9(1), 118-125 (2003).
26. Martinez-Torres F, Menon S, Pritsch M et al. Protocol for German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 8(1), 40 (2008).
27. Lopez C. Resistance to herpes simplex virus -type 1 (HSV-1). Curr. Top. Microbiol. Immunol. 92, 15-24 (1981).
28. Kastrukoff LF, Lau AS, Puterman ML. Genetics of natural resistance to herpes simplex virus type 1 latent infection of the peripheral nervous system in mice. J. Gen. Virol. 67(Pt 4), 613-621 (1986).
29. Simmons A. H-2-linked genes influence the severity of herpes simplex virus infection of the peripheral nervous system. J. Exp. Med. 169(4), 1503-1507 (1989).
30. Lundberg P, Welander P, Openshaw H et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. J. Virol. 77(21), 11661-11673 (2003).
31. Lundberg P, Ramakrishna C, Brown J et al. The immune response to herpes simplex virus type 1 infection in susceptible mice is a major cause of CNS pathology resulting in fatal encephalitis. J. Virol. 82(14), 7078-7088 (2008).
32. Ramakrishna C, Newo ANS, Shen Y-W, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog. 7(6), e1002071 (2011).
33. Rathinam VA, Fitzgerald KA. Innate immune sensing of DNA viruses. Virology 411(2), 153-162 (2011).
34. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138(3), 576-591 (2009).
35. Chew T, Taylor K, Mossman K. Innate and adaptive immune responses to herpes simplex virus. Viruses 1(3), 979-1002 (2009).
36. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140(6), 805-820 (2010).
37. Kurt-Jones EA, Chan M, Zhou S et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl. Acad. Sci. USA 101(5), 1315-1320 (2004).
38. Kurt-Jones EA, Belko J, Yu C et al. The role of Toll-like receptors in herpes simplex infection in neonates. J. Infect. Dis. 191(5), 746-748 (2005).
39. Sarangi PP, Kim B, Kurt-Jones E, Rouse BT. Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the Toll pathway in early inflammatory events in stromal keratitis. J. Virol. 81(20), 11128-11138 (2007).
40. Sato A, Linehan MM, Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl. Acad. Sci. USA 103(46), 17343-17348 (2006).
41. Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J. Immunol. 181(12), 8604-8612 (2008).
42. Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J. Virol. 77(20), 11158-11169 (2003).
43. Haas T, Metzger J, Schmitz F et al. The DNA sugar backbone 2' deoxyribose determines Toll-like receptor 9 activation. Immunity 28(3), 315-323 (2008).
44. Hochrein H, Schlatter B, O'Keeffe M et al. Herpes simplex virus type-1 induces IFN alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl Acad. Sci. USA 101(31), 11416-11421 (2004).
45. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 (HSV-1) activates murine natural interferon-producing cells (IPC) through Toll-like receptor 9. Blood 103(4), 1433-1437 (2003).
46. Wang JP, Bowen GN, Zhou S et al. Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J. Virol., 86(4), 2273-2281 (2011).
47. Lima GK, Zolini GP, Mansur DS et al. Toll-like receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia are critical to viral control during herpes simplex virus 1 infection. Am. J. Pathol. 177(5), 2433-2445 (2010).
48. Melchjorsen J. Sensing herpes: more than Toll. Rev. Med. Virol. 22(2), 106-121 (2012).
49. Paludan SRR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat. Rev. Immunol. 11(2), 143-154 (2011).
50. Holm CK, Jensen SB, Jakobsen MR et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 13(8), 737-743 (2012).
51. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10(10), 1065-1072 (2009).
52. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc. Ntl Acad. Sci. USA 109(47), 19386-19391 (2012).
53. Conrady CD, Drevets DA, Carr DJ. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing? J. Neuroimmunol. 220(1-2), 1-9 (2010).
54. Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol. J. 2(1), 59 (2005).
55. Paladino P, Mossman KL. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J. Interferon Cytokine Res. 29(9), 599-607 (2009).
56. Rasmussen SB, Sorensen LN, Malmgaard L et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 81(24), 13315-13324 (2007).
57. Lundberg P, Openshaw H, Wang M, Yang HJ, Cantin E. Effects of CXCR3 signaling on development of fatal encephalitis and corneal and periocular skin disease in HSV-infected mice are mouse-strain dependent. Invest. Ophthalmol. Vis. Sci. 48(9), 4162-4170 (2007).
58. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. J. Virol. 73(6), 5196-5200 (1999).
59. Luker GD, Prior JL, Song J, Pica CM, Leib DA. Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors. J. Virol. 77(20), 11082-11093 (2003).
60. Lekstrom-Himes JA, Leblanc RA, Pesnicak L, Godleski M, Straus SE. Gamma interferon impedes the establishment of herpes simplex virus type 1 latent infection but has no impact on its maintenance or reactivation in mice. J. Virol. 74(14), 6680-6683 (2000).
61. Ramakrishna C, Shen Y, Cantin E. Anti inflammatory role of IFN gamma in a viral model of encephalitis. J. Immunol. 186, 115-121 (2011).
62. Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard Jr. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J. Immunol. 175(7), 4189-4193 (2005).
63. Hu S, Sheng WS, Schachtele SJ, Lokensgard Jr. Reactive oxygen species drive herpes simplex virus (HSV)-1-induced proinflammatory cytokine production by murine microglia. J. Neuroinflammation 8, 123 (2011).
64. Marques CP, Hu S, Sheng W, Lokensgard Jr. Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection. Virus Res. 121(1), 1-10 (2006).
65. Simmons A, La Vista AB. Neural infection in mice after cutaneous inoculation with HSV-1 is under complex host genetic control. Virus Res. 13(3), 263-270 (1989).
66. Pedersen EB, Haahr S, Mogensen SC. X-linked resistance of mice to high doses of herpes simplex virus type 2 correlates with early interferon production. Infect. Immun. 42(2), 740-746 (1983).
67. Ellermann-Eriksen S, Liberto MC, Iannello D, Mogensen SC. X-linkage of the early in vitro alpha/beta interferon response of mouse peritoneal macrophages to herpes simplex virus type 2. J. Gen. Virol. 67(Pt 6), 1025-1033 (1986).
68. Ellermann-Eriksen S, Sommerlund M, Mogensen SC. Differential sensitivity of macrophages from herpes simplex virus-resistant and -susceptible mice to respiratory burst priming by interferon-alpha/beta. J. Gen. Virol. 70(Pt 8), 2139-2147 (1989).
69. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW. Interferons regulate the phenotype of wild type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189(4), 663-672 (1999).
70. Vollstedt S, Arnold S, Schwerdel C et al. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J. Virol. 78(8), 3846-3850 (2004).
71. Zhang S-Y, Jouanguy E, Ugolini S et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317(5844), 1522-1527 (2007).
72. Casrouge A, Zhang S-Y, Eidenschenk C et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314(5797), 308-12(2006).
73. Guo Y, Audry M, Ciancanelli M et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency. TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208(10), 2083-2098 (2011).
74. Fukui R, Miyake K. Controlling systems of nucleic acid sensing-TLRs restrict homeostatic inflammation. Exp. Cell Res. 318(13), 1461-1466 (2012).
75. Lopez CB, Hermesh T. Systemic responses during local viral infections: type I IFNs sound the alarm. Curr. Opin. Immunol. 23(4), 495-499 (2010).
76. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11(11), 762-774 (2011).
77. Hermesh T, Moltedo B, Moran TM, Lûpez CB. Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell Host Microbe 7(5), 343-353 (2010).
78. Seo S-U, Kwon H-J, Ko H-J et al. Type I interferon signaling regulates Ly6C monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 7(2), e1001304 (2011).
79. Boiko JR, Borghesi L. Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine 57(1), 1-8 (2012).
80. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 119(13), 2991-3002 (2012).
81. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11(10), 685-692 (2011).
82. Halford WP, Balliet JW, Gebhardt BM. Re evaluating natural resistance to herpes simplex virus type 1. J. Virol. 78(18), 10086-10095 (2004).
83. Ellermann-Eriksen S, Justesen J, Mogensen SC. Genetically determined difference in the antiviral action of alpha/beta interferon in cells from mice resistant or susceptible to herpes simplex virus type 2. J. Gen. Virol. 67(Pt 9), 1859-1866 (1986).
84. Peters N, Fesl G, Theil D et al. Subacute herpes simplex encephalitis presenting as relapsing encephalitis. J. Neurol. 257(5), 843-845 (2010).
85. Brown WD, Bearer EL, Donahue JE. Chronic active herpes simplex type 2 encephalitis in an asymptomatic immunocompetent child. J. Child Neurol. 25(7), 901-908 (2010).
86. Looney JR, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract. Res. Clin. Heamatol. 19(1), 3-25 (2006).
87. Kotlan B, Stroncek DF, Marincola FM. Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy 1(6), 995-1015 (2009).
88. Clynes R. Protective mechanisms of IVIG. Curr. Opin. Immunol. 19(6), 646-651 (2007).
89. Durandy A, Kaveri SV, Kuijpers TW et al. Intravenous immunoglobulins -understanding properties and mechanisms. Clin. Exp. Immunol. 158(Suppl. 1), 2-13 (2009).
90. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol. Rev. 236(1), 265-275 (2010).
91. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29(12), 608-615 (2008).
92. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787), 670-673 (2006).
93. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel Th2 pathway. Nature 475(7354), 110-113 (2011).
94. Erlich KS, Dix RD, Mills J. Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin. Antimicrob. Agents Chemother. 31(7), 1006-1009 (1987).
95. Getts DR, Terry RL, Getts MT et al. Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med. 205(10), 2319-2337 (2008).
96. Cantin EM, Hinton DR, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J. Virol. 69(8), 4898-4905 (1995).
97. Cheng H, Tumpey TM, Staats HF, Van Rooijen N, Oakes JE, Lausch RN. Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection. Invest. Ophthalmol. Vis. Sci. 41(6), 1402-1409 (2000).
98. Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J. Virol. 70(1), 264-271 (1996).
99. Decman V, Freeman ML, Kinchington PR, Hendricks RL. Immune control of HSV-1 latency. Viral Immunol. 18(3), 466-473 (2005).
100. Marques CP, Cheeran MCJ, Palmquist JM, Hu S, Urban SL, Lokensgard Jr. Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J. Immunol. 181(9), 6417-6426 (2008).
101. Armien AG, Hu S, Little MR et al. Chronic cortical and subcortical pathology with associated neurological deficits ensuing experimental herpes encephalitis. Brain Pathol. 20(4), 738-750 (2010).
102. Meyding-Lamade U, Lamade W, Kehm R et al. Herpes simplex virus encephalitis. chronic progressive cerebral MRI changes despite good clinical recovery and low viral load -an experimental mouse study. Eur. J. Neurol. 6(5), 531-538 (1999).
103. Meyding-Lamade UK, Lamade WR, Wildemann BT, Sartor K, Hacke W. Herpes simplex virus encephalitis: chronic progressive cerebral magnetic resonance imaging abnormalities in patients despite good clinical recovery. Clin. Infect. Dis. 28(1), 148-149 (1999).
104. Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal herpes encephalitis. J. Neurovirol. 6(1), 25-32 (2000).
105. Kimberlin DW, Whitley RJ, Wan W et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 365(14), 1284-1292 (2011).
106. Openshaw H, Cantin EM. Corticosteroids in herpes simplex virus encephalitis. J. Neurol. Neurosurg. Psychiatry 76(11), 1469 (2005).
107. Sergerie Y, Boivin G, Gosselin D, Rivest S. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J. Infect. Dis. 195(6), 817-825 (2007).
108. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 94(6), 557-572 (1998).
109. Lu YC, Fan HC, Wang CC, Cheng SN. Concomitant use of acyclovir and intravenous immunoglobulin rescues an immunocompromised child with disseminated varicella caused multiple organ failure. J. Pediatr. Hematol. Oncol. 33(8), e350-e351 (2011).
110. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin. Rev. Allergy Immunol. 42(2), 247-255 (2012).
111. Niimi N, Kohyama K, Kamei S, Matsumoto Y. Intravenous immunoglobulin therapy prevents development of autoimmune encephalomyelitis and suppresses activation of matrix metalloproteinases. Neuropathology, 31(4), 392-400 (2011).
112. Lehmann HC, Hartung H-P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J. Neuroimmunol. 231(1-2), 61-69 (2011).
113. Dalai SK, Pesnicak L, Miller GF, Straus SE. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J. Neurovirol. 8(1), 35-44 (2002).
114. Schachtele SJ, Hu S, Little MR, Lokensgard Jr. Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J Neuroinflammation 7, 35 (2010).
115. Milatovic D, Zhang Y, Olson SJ et al. Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2-isoprostanes and F4-neuroprostanes. J. Neurovirol. 8(4), 295-305 (2002).
116. Valyi-Nagy T, Olson SJ, Valyi-Nagy K, Montine TJ, Dermody TS. Herpes simplex virus type 1 latency in the murine nervous system is associated with oxidative damage to neurons. Virology 278(2), 309-321 (2000).
117. Gonzalez-Dosal R, Horan KA, Paludan SRR. Mitochondria-derived reactive oxygen species negatively regulates immune innate signaling pathways triggered by a DNA virus, but not by an RNA virus. Biochem. Biophys. Res. Commun. 418(4), 806-810 (2012).
118. Gonzalez-Dosal R, Horan KA, Rahbek SH et al. HSV infection induces production of ROS, which potentiate signaling from pattern recognition receptors: role for S-glutathionylation of TRAF3 and 6. PLoS Pathog. 7(9), e1002250 (2011).
119. Vlahos R, Stambas J, Bozinovski S, Broughton BRS, Drummond GR, Selemidis S. Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation. PLoS Pathog. 7(2), e1001271 (2011).
120. Schachtele SJ, Hu S, Lokensgard Jr. Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One 7(4), e36216 (2012).
121. ClinicalTrials.gov. www.clinicaltrials.gov